AstraZeneca’s stomach cancer drug clears bar for extending overall survival in late-stage study
The drug cut the risk of death by 53% and showed fewer serious side effects, though its progression-free survival goal fell short.
- On Sunday, AstraZeneca reported Phase III results showing its cancer drug sonesitatug vedotin cut the likelihood of death by 42% among previously treated patients with advanced gastric cancer.
- In the CLARITY-Gastric01 trial, researchers compared Sone-Ve against the investigator's choice of chemotherapy for patients whose tumors expressed the Claudin 18.2 protein on at least 25% of cells.
- Median overall survival reached 10.0 months with Sone-Ve versus 5.0 months on chemotherapy, representing a 53% reduction in the risk of death for patients in third-line or later settings.
- Susan Galbraith, executive vice president of oncology haematology research and development at AstraZeneca, called the 5-month improvement "very clinically significant" and confirmed the company is preparing to file for regulatory approval.
- AstraZeneca is testing the drug in the CLARITY-Gastric02 Phase III trial as a potential first-line treatment, although Sone-Ve missed its progression-free survival goal in the recent study.
24 Articles
24 Articles
AstraZeneca reported that its experimental drug against stomach cancer reduced the risk of death in patients with advanced disease by 53%.
AstraZeneca’s stomach cancer drug extends overall survival, late-stage trial data finds - Regional Media News
By Bhanvi Satija MADRID, Oct 25 (Reuters) - AstraZeneca's experimental drug sone-ve helped patients with advanced stomach cancer who had received at least two prior treatments to live longer than analysts had expected, according to late-stage trial data presented on Sunday. Patients on the drug [...]
Created the antibody-drug that works as a ?horse of Troy? against tumors. The innovative technology in precision oncology has proven to be...
AstraZeneca’s stomach cancer drug clears bar for extending overall survival in late-stage study
By Bhanvi Satija MADRID, Oct 25 (Reuters) - AstraZeneca's experimental drug sone-ve helped patients with advanced stomach cancer who had received at least two prior treatments to live longer than analysts had expected, according to late-stage trial da...
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
